Humanin
A mitochondria-associated peptide frequently discussed in longevity circles for cytoprotective and metabolic-interest pathways.
Also appears in: Weight Loss
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Anti-Aging. Also surfaces under Weight Loss for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 7 trials · 527 PubMed results
Current evidence for Humanin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Humanin has 4 name-matched clinical trials (highest phase: no phased trial) and 527 PubMed-indexed publications and is not FDA-approved. Note: 3 retracted publications in the literature.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What humanin is
Humanin is a mitochondria-associated peptide that appears in longevity and cell-protection discussions. It is usually framed around stress resistance, metabolic signaling, or age-related research interest.
Why it matters
Humanin helps broaden the anti-aging category beyond generic cosmetic language. It represents the more mechanism-heavy side of the longevity peptide conversation.
Regulatory context
Humanin is not FDA approved in the United States and belongs in the research-market category.
Practical reading note
Longevity peptides often attract high-concept marketing, so it is worth separating interesting biology from any claim of proven clinical anti-aging benefit.